US approves Swiss firm's cervical cancer test

Apr 20, 2011

Swiss pharmaceutical giant Roche has been given the green light by US authorities to market its test for screening cervical cancer, the company announced on Wednesday.

The US FDA has approved the cobas HPV () Test which identifies women with the highest risk of developing .

It is the only FDA-approved cervical cancer screening test that identifies genotypes 16 and 18, the two most aggressive forms of the potentially-fatal virus, at the same time as other high-risk forms, the company said.

Roche estimates that more than 55 million cervical smear tests are carried out in the US every year.

Last week the firm reported a nine percent fall in its first-quarter sales compared with a year ago, hurt by a strong Swiss franc.

Revenues for the first three months of the year reached 11.1 billion francs ($12.5 billion dollars, 8.6 billion euros).

The Basel-based group confirmed its full-year target, with group sales expected to grow at "low single-digit rates in local currencies."

Explore further: Gene marker may predict breast cancer response to tamoxifen

add to favorites email to friend print save as pdf

Related Stories

FDA considers expanded use of HPV vaccine

Mar 20, 2008

Pharmaceutical manufacturer Merck & Co. Inc. said the U.S. Food and Drug Administration will consider expanding the use of its cervical cancer vaccine.

Cervical cancer screening: Too many are left unprotected

Sep 19, 2007

The decline in cervical cancer is a success story of cancer research. Although there are reasons to be optimistic about even further decreases in cervical cancer incidence, there still remain some women who are not screened. ...

Recommended for you

User comments : 0